Kamada management will host an investment community conference call on Thursday, August 14, 2014 beginning at 8:30 a.m. Eastern time
Positive clinically meaningful efficacy signs in the inhaled AAT group including an approximate 50% reduction in severe exacerbation rates versus placebo
Continues with plans to submit for licensure in Europe in Q4 2014
Conference call begins at 8:30 a.m. Eastern time
Kamada announces financial results for the three months ended March 31, 2014
Lowers time from preparation to finish for patients with Alpha-1 Antitrypsin Deficiency by more than 75%
Preliminary human and animal studies indicate that AAT may considerably reduce the severity of GVHD, which is one of the key, life threatening complications of allogeneic stem cell transplantation.
NESS ZIONA, Israel (March 24, 2014) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a new Phase 2 U.S. clinical trial of its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD, or Inherited Emphysema). This trial is […]
Affirms plans for EMA submission in the second half of 2014
NESS ZIONA, Israel (March 5, 2014) – Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation a Phase 2/3 clinical trial of Glassia®, the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D). In T1D, autoimmune attacks occur […]
NESS ZIONA, Israel (March 4, 2014) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company, focused on orphan indications, announces that it has completed enrollment in its U.S. Phase 2/3 clinical trial of KamRAB® as a post-exposure prophylaxis (PEP) for rabies. KamRAB is Kamada's human rabies immune globulin, currently marketed for this […]
NESS ZIONA, Israel (February 24, 2014) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that Company management will ring the Opening Bell at The NASDAQ MarketSite in Times Square, New York at 9:30 a.m. ET on Tuesday, February 25, 2014. David Tsur, Co-Founder and Chief Executive […]